- Home
- IMVT vs HUBG Comparison
IMVT vs HUBG Comparison
Compare IMVT & HUBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- HUBG
- Stock Information
- Founded
- IMVT 2018
- HUBG 1971
- Country
- IMVT United States
- HUBG United States
- Employees
- IMVT N/A
- HUBG N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- HUBG Oil Refining/Marketing
- Sector
- IMVT Health Care
- HUBG Consumer Discretionary
- Exchange
- IMVT Nasdaq
- HUBG Nasdaq
- Market Cap
- IMVT 2.7B
- HUBG 2.1B
- IPO Year
- IMVT N/A
- HUBG 1996
- Fundamental
- Price
- IMVT $24.26
- HUBG $38.61
- Analyst Decision
- IMVT Buy
- HUBG Buy
- Analyst Count
- IMVT 9
- HUBG 10
- Target Price
- IMVT $27.71
- HUBG $40.10
- AVG Volume (30 Days)
- IMVT 1.5M
- HUBG 629.6K
- Earning Date
- IMVT 11-10-2025
- HUBG 10-30-2025
- Dividend Yield
- IMVT N/A
- HUBG 1.29%
- EPS Growth
- IMVT N/A
- HUBG N/A
- EPS
- IMVT N/A
- HUBG 1.74
- Revenue
- IMVT N/A
- HUBG $3,728,870,000.00
- Revenue This Year
- IMVT N/A
- HUBG N/A
- Revenue Next Year
- IMVT N/A
- HUBG $3.52
- P/E Ratio
- IMVT N/A
- HUBG $22.23
- Revenue Growth
- IMVT N/A
- HUBG N/A
- 52 Week Low
- IMVT $12.72
- HUBG $30.75
- 52 Week High
- IMVT $29.49
- HUBG $52.24
- Technical
- Relative Strength Index (RSI)
- IMVT 63.13
- HUBG 65.38
- Support Level
- IMVT $21.86
- HUBG $34.53
- Resistance Level
- IMVT $24.07
- HUBG $39.19
- Average True Range (ATR)
- IMVT 1.25
- HUBG 0.98
- MACD
- IMVT -0.18
- HUBG 0.37
- Stochastic Oscillator
- IMVT 83.68
- HUBG 86.92
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About HUBG Hub Group Inc.
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.